We are live on ! Find out more
Citadel Advisors

Citadel Advisors Portfolio holdings

AUM $618B
1-Year Est. Return 30.34%
 

Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.

This Fund
S&P 500
This Quarter Est. Return
-3.97%
1 Year Est. Return
+30.34%
3 Year Est. Return
+94.87%
5 Year Est. Return
+105.94%
10 Year Est. Return
+434.06%
AUM
$484B
AUM Growth
-$4.92B
Cap. Flow
+$23.6B
Cap. Flow %
4.87%
Top 10 Hldgs %
31.76%
Holding
15,382
New
1,669
Increased
5,510
Reduced
5,992
Closed
1,922

Sector Composition

Rank Sector Weight
1 Technology 2.72%
2 Healthcare 2.38%
3 Financials 2.3%
4 Consumer Discretionary 1.76%
5 Industrials 1.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
STCN
13226
DELISTED
Steel Connect, Inc. Common Stock
STCN
$13K ﹤0.01%
1,099
-2,212
-67% -$26.5K
CUEN
13227
DELISTED
Cuentas Inc. Common Stock
CUEN
$13K ﹤0.01%
789
-1,683
-68% -$26K
GROM
13228
PUT
DELISTED
Grom Social Enterprises Inc. Common Stock
GROM
$13K ﹤0.01%
+21
New +$17.5K
TUEM
13229
CALL
DELISTED
Tuesday Morning Corp
TUEM
$13K ﹤0.01%
+380
New +$18.3K
LOGC
13230
CALL
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$13K ﹤0.01%
+18,800
New +$20.6K
NBEV
13231
PUT
DELISTED
NewAge, Inc. Common Stock (Delaware)
NBEV
$13K ﹤0.01%
22,800
-10,200
-31% -$7.3K
JP
13232
DELISTED
Jupai Holdings Limited American depositary shares, each representing six ordinary shares
JP
$13K ﹤0.01%
17,606
-33,615
-66% -$24.6K
AIHS icon
13233
Senmiao Technology Ltd
AIHS
$22.6M
$12K ﹤0.01%
+508
New +$15.2K
CHR icon
13234
Cheer Holding
CHR
$3.4M
$12K ﹤0.01%
+7
New +$11.2K
LSTA icon
13235
PUT
Lisata Therapeutics
LSTA
$9.55M
$12K ﹤0.01%
1,093
-534
-33% -$6.11K
NERV icon
13236
Minerva Neurosciences
NERV
$199M
$12K ﹤0.01%
1,842
-4,504
-71% -$27.6K
PLX icon
13237
PUT
Protalix BioTherapeutics
PLX
$198M
$12K ﹤0.01%
10,900
-4,800
-31% -$4.4K
PZG icon
13238
Paramount Gold Nevada
PZG
$124M
$12K ﹤0.01%
19,302
-16,879
-47% -$11.7K
BNKK
13239
Bonk Inc
BNKK
$8.4M
$12K ﹤0.01%
310
-3,888
-93% -$139K
SLDB icon
13240
Solid Biosciences
SLDB
$900M
$12K ﹤0.01%
691
-3,906
-85% -$68.9K
TRX icon
13241
CALL
TRX Gold Corp
TRX
$344M
$12K ﹤0.01%
39,900
-36,600
-48% -$13.5K
QNTM
13242
PUT
Quantum Biopharma Class B Subordinate Voting Shares
QNTM
$22.1M
$12K ﹤0.01%
211
-117
-36% -$7.08K
NMTR
13243
PUT
DELISTED
9 Meters Biopharma
NMTR
$12K ﹤0.01%
1,000
-3,355
-77% -$45.8K
NVSAW
13244
DELISTED
New Vista Acquisition Corp. Warrant
NVSAW
$12K ﹤0.01%
31,133
+1,340
+4% +$630
LCI
13245
CALL
DELISTED
Lannett Company, Inc.
LCI
$12K ﹤0.01%
3,650
-23,350
-86% -$103K
LCI
13246
PUT
DELISTED
Lannett Company, Inc.
LCI
$12K ﹤0.01%
+3,875
New +$17K
LFTRW
13247
DELISTED
Lefteris Acquisition Corp. Warrant
LFTRW
$12K ﹤0.01%
46,197
-3,803
-8% -$1.74K
NAVB
13248
CALL
DELISTED
Navidea Biopharmaceuticals Inc.
NAVB
$12K ﹤0.01%
14,700
+4,000
+37% +$3.67K
CHNR icon
13249
China Natural Resources
CHNR
$5.15M
$11K ﹤0.01%
300
-828
-73% -$29.6K
ASLN
13250
PUT
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$11K ﹤0.01%
300
+10
+3% +$372

Similar funds

Citadel Advisors's Q1 2022 Portfolio in Review

As of Q1 2022, Citadel Advisors held 15,382 positions worth $484B, down 1% from $489B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Citadel Advisors deployed $23.6B of net new capital in Q1 2022, opening 1,669 new positions and adding to 5,510 existing holdings. Its largest new stake was iShares 20+ Year Treasury Bond ETF: 3,151,731 shares worth $416M.

By sector, the portfolio is most concentrated in Technology at 2.7% of assets, down from 3.1% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was NVIDIA, an estimated $518M trimmed.

  • Citadel Advisors's largest Q1 2022 buy was iShares 20+ Year Treasury Bond ETF: 3,151,731 shares worth $416M.
  • Citadel Advisors added most to State Street SPDR S&P 500 ETF Trust in Q1 2022, an estimated $555M increase.
  • Citadel Advisors's biggest Q1 2022 reduction was NVIDIA, cutting an estimated $518M.
  • Citadel Advisors fully exited IHS Markit Ltd. Common Shares in Q1 2022, selling an estimated $535M.
  • Citadel Advisors's ten largest holdings make up 32% of its $484B portfolio in Q1 2022.
  • Citadel Advisors opened 1,669 new positions and closed 1,922 in Q1 2022.
  • Citadel Advisors's portfolio value fell 1% quarter-over-quarter to $484B.

Based on Citadel Advisors's 13F filing for Q1 2022, filed 16 May 2022.